Pharmazz is a privately held company developing novel products in critical care medicine. The U.S. Food and Drug Administration (FDA) has approved two phase III INDs for Centhaquine as an agent for hypovolemic shock and Sovateltide for cerebral ischemic stroke. In addition, Pharmazz obtained marketing authorization for two of its first-in-class drug molecules, Centhaquine and Sovateltide, for hypovolemic shock and ischemic stroke, respectively, in India. Pharmazz has partnered with Sun Pharmaceutical to market Sovateltide for cerebral ischemic stroke patients in India. In addition, Pharmazz has partnered with Dr. Reddy's Laboratories to market Centhaquine, a resuscitative agent, in India. Additional information may be found on the Company's website, www.pharmazz.com.